Carlos Garcia Palenciano

Martínez-García JJ, Martínez-Banaclocha H, Angosto-Bazarra D, de Torre-Minguela C, Baroja-Mazo A, Alarcón-Vila C, Martínez-Alarcón L, Amores-Iniesta J, Martín-Sánchez F, Ercole GA, Martínez CM, González-Lisorge A, Fernández-Pacheco J, Martínez-Gil P, Adriouch S, Koch-Nolte F, Luján J, Acosta-Villegas F, Parrilla P, García-Palenciano C, Pelegrin P. P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis. Nat Commun. 2019 Jun 20;10(1):2711. doi: 10.1038/s41467-019-10626-x. PubMed PMID: 31221993; PubMed Central PMCID: PMC6586640.

AÑO: 2019; IF: 16.6

31221993

Alarcón-Vila C, Baroja-Mazo A, de Torre-Minguela C, Martínez CM, Martínez-García JJ, Martínez-Banaclocha H, García-Palenciano C, Pelegrin P. CD14 release induced by P2X7 receptor restricts inflammation and increases survival during sepsis. Elife. 2020 Nov 2;9. pii: e60849. doi: 10.7554/eLife.60849. PubMed PMID: 33135636; PubMed Central PMCID: PMC7690950.

AÑO: 2020; IF: 7.7

33135636

Gómez-Ruiz ÁJ, González-Gil A, Gil J, Alconchel F, Navarro-Barrios Á, Gil-Gómez E, Martínez J, Nieto A, García-Palenciano C, Cascales-Campos PA. Acute renal disease in patients with ovarian peritoneal carcinomatosis treated with cytoreduction and HIPEC: the influence of surgery and the cytostatic agent used. Langenbecks Arch Surg. 2021 Nov;406(7):2449-2456. doi: 10.1007/s00423-021-02279-6. Epub 2021 Jul 20. PubMed PMID: 34283300.

AÑO: 2021; IF: 2.895

34283300

Adánez Martínez MG, Leal Costa C, García López JA, Torres Ganfornina M, Ramos Morcillo AJ, Hernández Ruipérez T, García Palenciano C, Díaz Agea JL. Perception of level of knowledge, skills, and safety before and after training to perform videolaryngoscopy with the Intubox barrier system for airway management in patients with COVID-19. Emergencias. 2021 Abr;33(2):93-99. English, Spanish. PubMed PMID: 33750049.

AÑO: 2021; IF: 5.345

33750049

Hurtado-Navarro L, Cuenca-Zamora EJ, Zamora L, Bellosillo B, Such E, Soler-Espejo E, Martinez-Banaclocha H, Hernandez-Rivas JM, Marco-Ayala J, Martinez-Alarcon L, Linares-Latorre L, Garcia-Avila S, Amat-Martinez P, Gonzalez T, Arnan M, Pomares-Marin H, Carreno-Tarragona G, Chen-Liang TH, Herranz MT, Garcia-Palenciano C, Morales ML, Jerez A, Lozano ML, Teruel-Montoya R, Pelegrin P, Ferrer-Marin F. NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy. Cell Rep Med. 2023 Dec 19;4(12):101329. doi: 10.1016/j.xcrm.2023.101329. PubMed PMID: 38118408.

AÑO: 2023; IF: 14.3

38118408